Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials.

Extensive small cell lung cancer (ESCLC) is an aggressive neuroendocrine malignancy and represents 15% of all lung cancers [1]. Despite high response rate to upfront chemotherapy (CT) with either cisplatin or carboplatin plus etoposide up to 4-6 courses, most patients relapse within six months and median overall survival (OS) is 10 months [2,3].